Haloperidol Crescent Pharma International

Haloperidol Crescent Pharma International is a prescription oral medication containing the active ingredient haloperidol, a butyrophenone antipsychotic. The product is manufactured by Crescent Pharma International for the European market and is supplied in tablet form, though specific strength information is not disclosed. It is classified under ATC code N05AD01 and acts as a dopamine D2 receptor antagonist used in the management of certain psychiatric conditions.

Haloperidol Crescent Pharma International is indicated for the treatment of several psychiatric disorders where dopamine blockade is therapeutic.

- Management of schizophrenia, including both chronic maintenance and acute exacerbations. - Treatment of acute psychotic episodes associated with bipolar disorder or major depressive disorder. - Reduction of motor and vocal tics in patients with Tourette syndrome. - Control of severe agitation or aggression in inpatient or emergency settings when rapid symptom relief is required. - Adjunctive use for psychosis secondary to neurological diseases such as Huntington’s disease or Parkinson’s disease medication‑induced psychosis.

The safety profile of haloperidol includes a range of neurological, cardiovascular and metabolic effects that vary in frequency.

Common: - Extrapyramidal symptoms such as tremor, rigidity, and akathisia. - Drowsiness or sedation. - Dry mouth and increased salivation. - Constipation or gastrointestinal discomfort.

Serious: - Tardive dyskinesia, a potentially irreversible movement disorder. - Neuroleptic malignant syndrome, characterized by fever, muscle rigidity, and autonomic instability. - QT interval prolongation leading to cardiac arrhythmias.

Clinicians should evaluate patient‑specific factors and monitor for adverse events when prescribing haloperidol.

- Assess cardiovascular risk, especially in patients with known QT prolongation or electrolyte disturbances. - Use the lowest effective dose and limit duration to reduce risk of tardive dyskinesia. - Monitor for signs of neuroleptic malignant syndrome, particularly during dose escalation. - Caution in patients with hepatic or renal impairment, as clearance may be altered. - Evaluate for potential worsening of Parkinsonian symptoms in individuals with pre‑existing movement disorders. - Consider pregnancy and lactation status; haloperidol crosses the placenta and is excreted in breast milk.

Haloperidol may interact with several medications that affect its metabolism or cardiac conduction.

Avoid: - Concurrent use with other dopamine antagonists or high‑potency antipsychotics, which can increase extrapyramidal risk. - Co‑administration with drugs that significantly prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics). - Strong CYP3A4 inhibitors such as ketoconazole or clarithromycin, which raise haloperidol plasma levels.

Use with caution: - CYP3A4 inducers like carbamazepine or rifampin, which may reduce efficacy. - CNS depressants including benzodiazepines, opioids, or alcohol, which can enhance sedation. - Anticholinergic agents, which may mask early signs of extrapyramidal symptoms.